Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma

Abstract Spontaneous canine malignant melanoma provides an excellent pre‐clinical model to study DNA vaccines for melanoma immunotherapy. A USDA‐approved xenogeneic human tyrosinase (huTYR) plasmid DNA vaccine delivered intramuscularly induces detectable immune responses and has clinical activity in some dogs with melanoma. The objective of this pilot study was to evaluate the feasibility, safety and immunogenicity of huTYR plasmid DNA administered to the skin via microseeding in dogs with spontaneous melanoma. DNA microseeding utilizes a modified tattooing device as an alternate and potentially more potent delivery method for DNA immunization. DNA was delivered to shaved inner thigh skin of six companion dogs with melanoma approximately every 14 days for a planned total of four vaccination time points. An anti‐huTYR ELISA was used to test pre‐ and post‐treatment sera. Biopsies of treated skin were obtained for detection of huTYR transgene expression. DNA microseeding was well tolerated with no significant toxicity detected beyond local site irritation, and there were no signs of autoimmunity. huTYR‐expressing cells were observed in biopsies of huTYR DNA microseeding sites. Increased humoral anti‐huTYR antibodies were seen in two of five evaluable dogs following microseeding compared to baseline. DNA microseeding is well tolerated in companion dogs with melanoma. Further investigation is needed to determine if combining DNA microseeding with other immunotherapy regimens potentiates this delivery platform for cancer immunotherapy.

[1]  M. Higginbotham,et al.  Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour‐bearing dogs: A phase I dose finding study , 2018, Veterinary and comparative oncology.

[2]  D. Vail,et al.  Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose‐finding study , 2017, Veterinary and comparative oncology.

[3]  S. Ferrone,et al.  Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4‐antigen electrovaccination , 2017, Veterinary and comparative oncology.

[4]  Chris Morrison.  DNA vaccines against Zika virus speed into clinical trials , 2016, Nature Reviews Drug Discovery.

[5]  P. Harari,et al.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. , 2016, Cancer research.

[6]  Richard G. Jarman,et al.  Vaccine Protection Against Zika Virus from Brazil , 2016, Nature.

[7]  James S Goydos,et al.  Acral Lentiginous Melanoma. , 2016, Cancer treatment and research.

[8]  D. Thamm,et al.  Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.

[9]  N. Sardesai,et al.  Chemokine Adjuvanted Electroporated-DNA Vaccine Induces Substantial Protection from Simian Immunodeficiency Virus Vaginal Challenge , 2015, Mucosal Immunology.

[10]  L. Finocchiaro,et al.  Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals , 2014, TheScientificWorldJournal.

[11]  B. Wahrén,et al.  DNA Vaccines: Recent Developments and the Future , 2014, Vaccines.

[12]  J. Hauptman,et al.  A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. , 2013, Veterinary and comparative oncology.

[13]  Paula T Hammond,et al.  Polymer multilayer tattooing for enhanced DNA vaccination. , 2013, Nature materials.

[14]  A. Odoi,et al.  Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase , 2012 .

[15]  L. Lembcke,et al.  Evaluation of tyrosinase expression in canine and equine melanocytic tumors. , 2012, American journal of veterinary research.

[16]  G. Winter,et al.  Devices for intradermal vaccination. , 2012, Vaccine.

[17]  T. Schumacher,et al.  DNA vaccines and intradermal vaccination by DNA tattooing. , 2012, Current topics in microbiology and immunology.

[18]  J. Wolchok,et al.  Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. , 2011, American journal of veterinary research.

[19]  M. Miller,et al.  Immunohistochemical Identification of Canine Melanocytic Neoplasms With Antibodies to Melanocytic Antigen PNL2 and Tyrosinase , 2011, Veterinary pathology.

[20]  D. Thamm,et al.  Spontaneous Companion Animal (Pet) Cancers , 2011 .

[21]  C. Khanna,et al.  Modeling opportunities in comparative oncology for drug development. , 2010, ILAR journal.

[22]  T. Schumacher,et al.  Optimization of intradermal vaccination by DNA tattooing in human skin. , 2008, Human gene therapy.

[23]  Alessandra Conversi,et al.  Comparative Analysis , 2009, Encyclopedia of Database Systems.

[24]  Q. Sattentau,et al.  Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. , 2008, Vaccine.

[25]  A. Goubier,et al.  Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. , 2008, Vaccine.

[26]  M. Paoloni,et al.  Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.

[27]  D. Hicklin,et al.  Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. , 2008, Human antibodies.

[28]  T. Olivry,et al.  Patch testing of experimentally sensitized beagle dogs: development of a model for skin lesions of atopic dermatitis. , 2006, Veterinary dermatology.

[29]  J. Wolchok,et al.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. , 2006, Cancer immunity.

[30]  R. Dubielzig,et al.  Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma , 2006, Cancer Immunology, Immunotherapy.

[31]  Chien-Fu Hung,et al.  A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression , 2005, Nature Medicine.

[32]  H. Mizutani,et al.  Animal Models of Atopic Dermatitis , 2004 .

[33]  D. Tobin,et al.  A natural canine homologue of alopecia areata in humans , 2003, The British journal of dermatology.

[34]  J. Wolchok,et al.  Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Lamb,et al.  Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  T. Olivry,et al.  The ACVD task force on canine atopic dermatitis (V): biology and role of inflammatory cells in cutaneous allergic reactions. , 2001, Veterinary immunology and immunopathology.

[37]  F. Yao,et al.  In vivo gene transfer to skin and wound by microseeding. , 1998, The Journal of surgical research.

[38]  F. Marincola,et al.  Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. , 1998, Journal of immunotherapy.

[39]  K. Matthay,et al.  A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.

[40]  R. Rogers,et al.  Mucosal, genital, and unusual clinical variants of melanoma. , 1997, Mayo Clinic proceedings.

[41]  S. Helfand,et al.  Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. , 1996, Cellular immunology.

[42]  M. Lindstrom,et al.  Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[43]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[44]  E. Nabel,et al.  Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. , 1992, Human gene therapy.